Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Study of Risk Factors for IPMNs Degeneration at the Nancy CHRU 1 Multiple Myeloma 1 Leukemia, Myeloid 1

Interventions

Dexamethasone 420 Lenalidomide 265 Cyclophosphamide 246 Bortezomib 242 Melphalan 192 Calcium Dobesilate 166 fludarabine phosphate 112 daratumumab 103 Peripheral Blood Stem Cell Transplantation 99 carfilzomib 92 Thalidomide 90 Filgrastim 88 Mycophenolic Acid 82 fludarabine 81 pomalidomide 80 Whole-Body Irradiation 80 Busulfan 74 Tacrolimus 71 Granulocyte Colony-Stimulating Factor 66 Cyclosporine 58 dexamethasone acetate 56 ixazomib 55 Antilymphocyte Serum 50 dexamethasone 21-phosphate 49 auricularum 44 isatuximab 40 Etoposide 39 Radiotherapy 36 Stem Cell Transplantation 34 Methotrexate 33

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Multiple Myeloma × Sensitivity and Specificity × Clear all

NCT01886976 2016-01-28

CART-138

Chinese PLA General Hospital

Phase 1/2 Unknown

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡